Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2021)
37 slides from Ac Immune Sa's shareholder meeting presentation, Jun 25, 2021
Slide 1: Pioneering Precision Medicine for Neurodegeneration
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting | June 25, 2021 www.acimmune.com Version: 22.06.2021
Slide 2: Disclaimer
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securi
Slide 3: Agenda
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 3 Agenda 1. AC Immune’s leadership in neurodegenerative diseases 2. Achievements 2020/21 3. AC Immune’s business strategy 4. Pipeline update 5. SupraAntigen™ and clinical - stage vaccine prog
Slide 4: AC Immune's leadership in neurodegenerative diseases
1. AC Immune’s leadership in neurodegenerative diseases Andrea Pfeifer, CEO
Slide 5: "Firsts" reflect ACIU's leadership in NDD
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 2013 2014 2015 2017 2019 2020 2020 2021 2021 (1) Neurodegenerative diseases; (2) Alzheimer's disease; (3) Phosphorylated Tau; (4) Positron emission tomography; (5) Progre ssi ve supranuclear
Slide 6: Precision medicine is a key driver for effective treatments
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Precision medicine is a key driver for effective treatments Roadmap to successful therapies for neurodegenerative diseases 6 ( 1 ) Reardon S, Nature 2018 ; ( 2 ) Pontecorvo MJ, et al . , Brai
Slide 7: Precision medicine for prevention and treatment of NDD
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Precision medicine for prevention and treatment of NDD 7 Ref : Jack et al.; Lancet Neurology 2010; Trojanowski et al., Alzheimer's & Dementia 2010; Jansen et al .; JAMA. 2015 Cognitively norm
Slide 8: The need for precision medicine
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission The need for precision medicine 8 Improved clinical trials, diagnosis and treatment of neurodegenerative diseases Co - pathologies in AD 1 and other NDD 2 may indicate a need for different th
Slide 9: Achievements 2020/21
2. Achievements 2020/21
Slide 10: Strong progress in 2020
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Strong progress in 2020 10 Continuing our track record of successful execution x Received second milestone payment of CHF 10 million from Lilly for small molecule Tau aggregation inhibitor x
Slide 11: AC Immune's business strategy
3. AC Immune’s business strategy
Slide 12: Execution of our three-pillar strategy: the 2021 focus
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Execution of our three - pillar strategy: the 2021 focus 12 Precision medicine Alzheimer’s disease (AD) Focused non - AD Parkinson’s 1 LATE 2 NeuroOrphan Diagnostics SupraAntigen ® & Morphome
Slide 13: Vision to become a global leader in precision medicine
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Vision to become a global leader in precision medicine 1 13 Developing breakthrough mono - and combination therapies for neurodegenerative diseases SupraAntigen ® Vaccines and antibodies spec
Slide 14: SupraAntigen and Morphomer platforms
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission SupraAntigen ® and Morphomer ® platforms An integrated approach to CNS 1 - specific therapies 14 (1) Central nervous system Clinically validated CNS - optimized Precision medicine enabling Co
Slide 15: Pipeline update
Click to add subtitle
Slide 16: Broad and robust pipeline in neurodegenerative diseases
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Broad and robust pipeline in neurodegenerative diseases Driven by validated proprietary technology platforms for sustained growth 16 TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL
Slide 17: Diversification into non-AD and non-CNS diseases
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission TARGET PRODUCT CANDIDATE INDICATION DISCOVERY PRECLINICAL PHASE 1 a - synuclein (a - syn) A - syn - PET 3 tracer PD 4 , a - synucleinopathies Anti - a - syn antibody PD, NeuroOrphan Morphomer
Slide 18: SupraAntigen platform and Clinical vaccine programs
5. SupraAntigen ® platform and Clinical vaccine programs
Slide 19: Proprietary SupraAntigen platform
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Proprietary SupraAntigen ® platform Generation of vaccines and monoclonal antibodies 19 Antibodies: Passive immunization (external antibody production) Vaccines: Active immunization (immune s
Slide 20: SupraAntigen: Key advantages/benefits
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission SupraAntigen ® : Key advantages/benefits 20 CANDIDATE DISCOVERY PRE - CLINICAL PH 1 PH 2 ACI - 35.030 (anti - pTau vaccine ) Semorinemab (anti - Tau antibody ) Crenezumab (anti - Abeta antibo
Slide 21: Anti-pTau vaccine ACI-35.030 key results and development status
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 21 Key results 2 ▪ Highly specific antibody response against aggregated pTau ▪ Preclinical: improvement of cognition, physical performance, behavior and survival; T - cell independent mode of
Slide 22: ACI-35.030 highly encouraging interim Phase 1b/2a results in AD
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission ACI - 35.030 – highly encouraging interim Phase 1b/2a results in AD 1 Achieved high titers of anti - pTau antibodies at potentially therapeutic levels in 100% of patients 22 (1) Alzheimer’s d
Slide 23: ACI-24 Abeta vaccine: upcoming milestones and Phase 2 design
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Upcoming milestones Q1 Q2 Q3 Q4 Milestone Phase 2 interim analysis (12 month) in Alzheimer’s disease Phase 2 interim analysis (18 month) in Alzheimer’s disease 23 Key results 2 ▪ Strong and r
Slide 24: ACI-24 Phase 1b in people with Down syndrome
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Study rationale ▪ DS population is at high risk of developing Alzheimer’s disease - like symptoms ▪ 75 – 100% of people with DS have Alzheimer’s disease - like symptoms by age 60 2 ▪ Unique p
Slide 25: Optimized anti-Abeta ACI-24 vaccine formulation
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Key results ▪ Primes, boosts and maintains polyclonal anti - Abeta IgG 2 response in two species of non - human primates (NHPs) ▪ Generates conformation - specific antibody responses targetin
Slide 26: Optimized ACI-24: Strong immune response against pyroglutamate Abeta
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Optimized anti - Abeta ACI - 24: Strong immune response against pyroglutamate Abeta 26 Ref.: AC Immune; Global Down Syndrome Forum 2021 (1) Pyroglutamate Cynomolgus serum – Day 120 Epitope ma
Slide 27: Optimized ACI-24: Superior recognition of pyroglutamate Abeta in NHPs
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Optimized anti - Abeta ACI - 24: Superior recognition of pyroglutamate Abeta in NHPs 1 27 Broader N - terminal sequence recognition compared to previous clinical - stage Abeta vaccines ■ The
Slide 28: Disruptive potential of SupraAntigen-V
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Disruptive potential of SupraAntigen ® - V Optimized vaccines delivering superior results in neurodegenerative diseases 28 (1) Synthetic Monophosphoryl Lipid A; (2) Synthetic oligodeoxynucleo
Slide 29: Near-term inflection points
6. Near - term inflection points
Slide 30: Multiple catalysts to drive further value creation in 2021
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 30 Multiple catalysts to drive further value creation in 2021 Q1 Q2 Q3 Q4 Clinical Tau pTau vaccine Interim Phase 1b/2a results (mid - dose) 1 of ACI - 35.030 Phase 1b/2a interim analysis (hi
Slide 31: Financial figures
7. Financial figures
Slide 32: Substantial funds from partnerships complement equity investments
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Substantial funds from partnerships complement equity investments 32 Distinguished institutional investors 1 Five private financing rounds IPO NASDAQ September 2016 Share capital offering of
Slide 33: First Quarter 2021 financial update
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 33 First Quarter 2021 financial update Strong cash position R&D expenses G&A expenses Other operating income ▪ CHF 216.1 million at March 31, 2021, compared to CHF 225.9 million at December 3
Slide 34: Strategic outlook
8. Strategic outlook
Slide 35: Drivers of value creation in 2021 and beyond
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission Drivers of value creation in 2021 and beyond 35 Sustained financial strength ▪ Strong balance sheet with potential for substantial partnership revenue ▪ Vision to become a fully integrated bi
Slide 36: AC Immune future directions
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission 36 (1) Central nervous system; (2) Limbic - predominant age - related TDP - 43 encephalopathy AC Immune future directions Expanding our capabilities and building a fully - integrated company
Slide 37: We continue to shape the future of neurodegeneration
NASDAQ: ACIU | Annual General Meeting 2021 © 2021 AC Immune. Not to be used or reproduced without permission We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine 37 AC Immune